PMID- 21551479
OWN - NLM
STAT- MEDLINE
DCOM- 20111230
LR  - 20181201
IS  - 1532-2092 (Electronic)
IS  - 1099-5129 (Linking)
VI  - 13
IP  - 9
DP  - 2011 Sep
TI  - Beneficial effect of pioglitazone on the outcome of catheter ablation in patients 
      with paroxysmal atrial fibrillation and type 2 diabetes mellitus.
PG  - 1256-61
LID - 10.1093/europace/eur131 [doi]
AB  - AIMS: Pioglitazone, one of the peroxisome proliferator-activated receptor-gamma 
      activators, possesses anti-inflammatory and antioxidant properties. In the 
      present study, we sought to identify the impact of pioglitazone on the outcome of 
      catheter ablation for paroxysmal atrial fibrillation (PAF). METHODS AND RESULTS: 
      We conducted a prospective observational cohort study of 150 consecutive patients 
      undergoing catheter ablation of drug-refractory PAF. All patients had a history 
      of type 2 diabetes mellitus (T2DM) and were divided based on whether they 
      received pioglitazone before ablation or not. After grouping, 51 patients treated 
      with pioglitazone and 99 control subjects were followed up at least 15 months 
      after ablation. After a single ablation, sinus rhythm was maintained in 44 
      patients (86.3%) of the pioglitazone group vs. 70 patients (70.7%) of the control 
      group (P = 0.034) without antiarrhythmic drug during a mean follow-up of 22.9 +/- 
      5.1 months. The second ablation was performed in 5 patients (9.8%) from the 
      pioglitazone group and in 24 patients (24.2%) from the control group (P = 0.034). 
      Multivariate logistic analysis showed left atrium diameter was associated with a 
      high risk of atrial tachyarrhythmias recurrence, and treatment with 
      renin-angiotensin system inhibitor as well as pioglitazone was associated with a 
      reduced atrial tachyarrhythmias recurrence rate. CONCLUSION: Pioglitazone 
      improved the preservation of sinus rhythm and reduced the reablation rate in 
      patients with PAF and T2DM after catheter ablation.
FAU - Gu, Jun
AU  - Gu J
AD  - Department of Cardiology, Shanghai Chest Hospital, Affiliated to Shanghai 
      Jiaotong University, 241 West Huaihai Road, Shanghai 200030, People's Republic of 
      China.
FAU - Liu, Xu
AU  - Liu X
FAU - Wang, Xinhua
AU  - Wang X
FAU - Shi, Haifeng
AU  - Shi H
FAU - Tan, Hongwei
AU  - Tan H
FAU - Zhou, Li
AU  - Zhou L
FAU - Gu, Jianing
AU  - Gu J
FAU - Jiang, Weifeng
AU  - Jiang W
FAU - Wang, Yuanlong
AU  - Wang Y
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20110507
PL  - England
TA  - Europace
JT  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal 
      of the working groups on cardiac pacing, arrhythmias, and cardiac cellular 
      electrophysiology of the European Society of Cardiology
JID - 100883649
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Aged
MH  - Atrial Fibrillation/drug therapy/*surgery
MH  - *Catheter Ablation
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Diabetic Cardiomyopathies/drug therapy/*surgery
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pioglitazone
MH  - Recurrence
MH  - Renin-Angiotensin System/drug effects
MH  - Tachycardia/drug therapy/surgery
MH  - Thiazolidinediones/*therapeutic use
MH  - Treatment Outcome
EDAT- 2011/05/10 06:00
MHDA- 2011/12/31 06:00
CRDT- 2011/05/10 06:00
PHST- 2011/05/10 06:00 [entrez]
PHST- 2011/05/10 06:00 [pubmed]
PHST- 2011/12/31 06:00 [medline]
AID - eur131 [pii]
AID - 10.1093/europace/eur131 [doi]
PST - ppublish
SO  - Europace. 2011 Sep;13(9):1256-61. doi: 10.1093/europace/eur131. Epub 2011 May 7.